Table 3.
Effect of inhibitors on vascular effect of nicotinic acid analogs 6-8.
| Compound | Vasorelaxant activity | |||||||
|---|---|---|---|---|---|---|---|---|
| −Inhibitora | +L-NAME (1mM) | +INDO (1mM) | +L-NAME (1mM) +INDO (1mM) | |||||
| Rmax (%) | ED50 (M) | Rmax (%) | ED50 (M) | Rmax (%) | ED50 (M) | Rmax (%) | ED50 (M) | |
| AChb | 121.7 ± 1.44 | 9.99 × 10-7 | 81.34 ± 0.77 | 5.44 × 10-7 | 68.78 ± 0.92 | 4.58 × 10-7 | 0 | − |
| 6b | 77.67±0.66 | 1.78 × 10-8 | 47.44 ± 0.44 | 3.55 × 10-8 | 46.05 ± 0.26 | 7.17 × 10-8 | 0 | − |
| 7b | 76.93±0.56 | 1.23 × 10-7 | 43.22 ± 0.66 | 3.88 × 10-7 | 36.49 ± 0.60 | 6.34 × 10-7 | 0 | − |
| 8b | 71.47±0.42 | 2.05 × 10-7 | 42.10 ± 0.65 | 3.43 × 10-7 | 37.63 ± 0.62 | 6.14 × 10-7 | 0 | − |
| SNPc | 120.81±1.18 | 3.16 × 10-7 | 116.70 ± 1.30 | 3.17 × 10-7 | 112.93 ± 0.61 | 3.16 × 10-7 | 104.98±1.41 | 3.17×10-7 |
a -Inhibitor: in the absence of L-NAME or INDO; b Data obtained from five experiments; c Data obtained from six experiments.